Universal reference book for medicines
Product name: HUMODAR K25-100 (HUMODAR K25-100)

Active substance: insulin human

Type: Human moderate-duration insulin with a rapid onset of action

Producer: Indar ZAO for the production of insulin (Ukraine)
Composition, form of production and packaging
Suspension for s / c injection
1 ml

insulin biphasic human semisynthetic 100 U

3 ml - cartridges (3) - packs cardboard.

3 ml - cartridges (5) - packs cardboard.

10 ml - bottles (1) "insulin" - packs cardboard.

INSTRUCTION FOR THE SPECIALIST.

Description of the drug approved by the manufacturer for the printed edition of 2010.

PHARMACHOLOGIC EFFECT

Humodar K25-100 is a preparation of human semisynthetic insulin of average duration of action.
The composition of the drug includes insulin soluble (25%) and insulin isophane (75%). It interacts with a specific receptor of the external cytoplasmic cell membrane and forms an insulin-receptor complex that stimulates intracellular processes, incl. synthesis of a number of key enzymes (hexokinase, pyruvate kinase, glycogen synthetase and others). Reduction of blood glucose is due to increased intracellular transport, increased absorption and assimilation by tissues, stimulation of lipogenesis, glycogenogenesis, a decrease in the rate of glucose production by the liver. The duration of action of insulin preparations is mainly due to the rate of absorption, which depends on several factors (for example, on the dose, method and site of administration), and therefore the profile of insulin activity is subject to significant fluctuations, both in different people and in the same rights. On the average, the onset of action of the drug after subcutaneous injection occurs 30 minutes later, the maximum effect is 1-3 hours, the duration of action is 12-16 hours.
PHARMACOKINETICS

Completeness of absorption and the beginning of the effect of insulin depends on the mode of administration (sc, v / m), the place of administration (abdomen, thigh, buttocks), the dose (volume of insulin administered), the concentration of insulin in the preparation, etc. Distributed in tissues unevenly;
does not penetrate the placental barrier and into breast milk. It is destroyed by insulinase mainly in the liver and kidneys. It is excreted by the kidneys (30-80%).
INDICATIONS

- diabetes in adults.

DOSING MODE

The drug is intended for administration.
The dose and time of administration of the drug are determined by the physician individually in each specific case based on the blood glucose level. On average, the daily dose of the drug ranges from 0.5 to 1 IU / kg body weight (depends on the individual characteristics of the patient and blood glucose level). The temperature of the insulin should be appropriate at room temperature. The drug is usually injected into the thigh. Injections can also be done in the anterior abdominal wall, buttock, or the deltoid muscle region of the shoulder. It is necessary to change the injection site within the anatomical area to prevent the development of lipodystrophy.
Patients with type 2 diabetes mellitus can be administered as a monotherapy with Humodar K25-100 (brevity of administration 2 times / day) and combined therapy with oral hypoglycemic agents.

Instructions to be given to the patient

The technique of injection with the use of insulin in vials

1. Disinfect the rubber membrane on the vial

2. Insert the air in the syringe in the amount corresponding to the required dose of insulin.
Insert air into the vial with insulin.
3. Turn the bottle with the syringe upside down and type the desired dose of insulin into the syringe.
Remove the needle from the vial and remove air from the syringe.Check the correctness of the dose of insulin.
4. Immediately inject.

The technique of injection with the use of insulin in cartridges

The cartridge with the Humodar K25-100 preparation is intended only for use in syringe pens.
Care should be taken to follow the instructions in the instructions for using the syringe pen for insulin administration.
Before using, make sure that there are no damages (for example, cracks) on the cartridge with Humodar K25-100.
Do not use the cartridge if there are any visible damage. After the cartridge is inserted into the syringe pen, a colored strip should be visible through the cartridge holder window.
Before placing the cartridge in the syringe pen, turn the cartridge up and down so that the glass ball moves from end to end of the cartridge.
This procedure should be repeated at least 10 times, until all the liquid becomes white and evenly turbid. Immediately after this, an injection must be made.
If the cartridge is already inside the pen syringe, turn it with the cartridge inside up and down at least 10 times.
This procedure must be repeated before each injection.
After the injection, the needle should remain under the skin for a minimum of 6 seconds.
Keep the button depressed until the needle is completely removed from the skin, thus ensuring the correct dose administration and limiting the possibility of blood or lymph flow into the needle or the insulin cartridge.
The cartridge with Humodar K25-100 preparation is intended only for individual use and can not be refilled.

Injection procedure

1.Double with your fingers take the fold of the skin, insert the needle into the base of the fold at an angle of about 45 ° and insert under the skin insulin.

2.After injection, the needle should remain under the skin for at least 6 seconds, in order to ensure that the insulin is injected completely.

3.If after removing the needle at the site of the injection, blood appears, gently press the place of the prick with your finger.

4. It is necessary to change the injection site.

SIDE EFFECT

Due to the effect on carbohydrate metabolism: hypoglycemic conditions (pallor of the skin, increased sweating, palpitation, tremor, hunger, agitation, paresthesia in the mouth, headache).
Pronounced hypoglycemia can lead to the development of hypoglycemic coma.
Allergic reactions: rarely - skin rash, Quincke's edema, extremely rarely - anaphylactic shock.

Local reactions: hyperemia, swelling and itching at the injection site, with prolonged use - lipodystrophy at the injection site.

Other: swelling, transient refractive disorders (usually at the beginning of therapy).

CONTRAINDICATIONS

- hypoglycemia;

- Hypersensitivity to insulin or other components of the drug.

PREGNANCY AND LACTATION

Restrictions on the treatment of diabetes mellitus with insulin during pregnancy are not, because
Insulin does not penetrate the placental barrier. When planning pregnancy and during it, it is necessary to intensify the treatment of diabetes. The need for insulin usually decreases in the first trimester of pregnancy and gradually rises in the II and III trimesters. During and immediately after delivery, the need for insulin can dramatically decrease. Shortly after birth, the need for insulin quickly returns to the level that was before pregnancy. There are no restrictions on the treatment of diabetes mellitus with insulin during lactation. However, it may be necessary to reduce the dose of insulin, so careful monitoring is necessary before stabilizing the need for insulin.
SPECIAL INSTRUCTIONS

On the background of insulin therapy, continuous monitoring of blood glucose levels is necessary.
The causes of hypoglycemia in addition to an overdose of insulin may include: drug substitution, skipping meals, vomiting, diarrhea, increased physical activity, diseases that reduce the need for insulin (liver and kidney function, hypofunction of the adrenal cortex, pituitary gland or thyroid gland), change of injection site, as well as interaction with other drugs.
Incorrect dosing or breaks in the introduction of insulin can lead to hyperglycemia.
Usually, the first symptoms of hyperglycemia develop gradually, over several hours or days. They include the appearance of thirst, increased urination, nausea, vomiting, dizziness, redness and dryness of the skin, dry mouth, loss of appetite.
The dose of insulin must be corrected in case of thyroid dysfunction, Addison's disease, hypopituitarism, liver and kidney dysfunction and diabetes mellitus in persons over 65 years of age.

Do not use the drug if, after shaking, the suspension does not turn white or evenly cloudy.

Correction of the dose of insulin may also be required if the patient increases the intensity of physical activity or changes the habitual diet.
Concomitant diseases, especially infections and conditions accompanied by fever, increase the need for insulin.
The transition from one type of insulin to another should be carried out under the control of blood glucose.

The drug lowers tolerance to alcohol.

Impact on the ability to drive vehicles and manage mechanisms

In connection with the primary appointment of insulin, a change in its type or in the presence of significant physical or mental stress, it is possible to reduce the ability to drive a car or to manage various mechanisms, as well as engaging in other potentially dangerous activities requiring increased attention and speed of mental and motor reactions.

OVERDOSE

Symptoms: an overdose may develop hypoglycemia.

Treatment: mild hypoglycemia can be eliminated by the patient himself, taking sugar or carbohydrate-rich foods, so it is recommended that patients with diabetes always carry sugar, sweets, cookies or sweet fruit juice.

In severe cases, if the patient lost consciousness, iv injected a 40% solution of dextrose (glucose);
in / m, sc, v / in - glucagon. After restoration of consciousness the patient is recommended to take food rich in carbohydrates, to prevent the repeated development of hypoglycemia.
DRUG INTERACTION

There are a number of drugs that affect the need for insulin.

The hypoglycemic effect of Chomodar K25-100 is enhanced by oral hypoglycemic drugs, MAO inhibitors, ACE inhibitors, carbonic anhydrase inhibitors, nonselective beta adrenoblockers, bromocriptine, octreotide, sulfonamides, anabolic steroids, tetracyclines, clofibrate, ketoconazole, mebendazole, pyridoxine, theophylline, cyclophosphamide, fenfluramine, preparations of lithium, quinidine, quinine, chloroquine, preparations containing ethanol.

The hypoglycemic effect of the drug is weakened by oral contraceptives, GCS, thyroid hormones, loop and thiazide diuretics, heparin, glucagon, somatotropin, estrogens, sulfinpyrazone, marijuana, epinephrine, histamine H 1 receptor blockers, tricyclic antidepressants, sympathomimetics, danazol, clonidine, slow calcium blockers channels, diazoxide, morphine, phenytoin, nicotine.

Under the influence of reserpine and salicylates, both weakening and enhancement of the action of the drug are possible.

Pentamidine can both enhance and weaken the hypoglycemic action of insulin.

Against the background of alcohol consumption, the need for insulin decreases, which requires correction of the dose of the drug.

TERMS OF RELEASE FROM PHARMACY

The drug is released by prescription.

TERMS AND CONDITIONS OF STORAGE

The drug is stored at a temperature of + 2 ° to + 8 ° C.
Do not freeze.
The vial with insulin that is used can be stored for 6 weeks, and the cartridge with insulin - for 3 weeks at room temperature (not above 25 ° C), provided that it is protected from direct exposure to heat and light.
Keep out of the reach of children.
Shelf life of the drug is 2 years.
Do not use after the expiration date printed on the package.
Alphabetical index of medicines:
A  B  V  G  D  E  J
Z  I  Y  K  L  M  N
O  P  R  S  T  U  F
H  C  CH  SH  E  U  Y
Rambler's Top100
Privacy policy:
Copyright 2009 - 2017. Universal reference book of medicines. All rights reserved.
When using site materials, an active hyperlink is required!